Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | unknown | Phase 1 | 78 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 |
| NCT01189942 | A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 9, 2020 | clinicaltrials |
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 | 50 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT02824042 | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | completed | Phase 1 | 63 | BayerINDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT03089645 | MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. | completed | Phase 1 | 39 | MedImmune LLCINDUSTRY | 2 | Jul 27, 2020 | clinicaltrials |
| NCT02747342 | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | completed | Phase 1 | 33 | Atridia Pty Ltd.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02955251 | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 61 | AbbVieINDUSTRY | 4 | Jul 20, 2020 | clinicaltrials |
| NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | completed | Phase 1 / Phase 2 | 267 | Hoffmann-La RocheINDUSTRY | 10 | Jun 11, 2020 | clinicaltrials |
| NCT01742286 | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | completed | Phase 1 | 83 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 9, 2020 | clinicaltrials |
| NCT02512237 | A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | terminated | Phase 1 | 9 | Zhejiang Medicine Co., Ltd.INDUSTRY | 2 | Jun 5, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT03936426 | Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ | completed | Phase 1 / Phase 2 | 5 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Apr 20, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 18, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | completed | Phase 1 | 196 | GlaxoSmithKlineINDUSTRY | 7 | Mar 16, 2020 | clinicaltrials |
| NCT00440726 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 31 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 4 | Feb 19, 2020 | clinicaltrials |
| NCT03068351 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | completed | Phase 1 | 24 | Hoffmann-La RocheINDUSTRY | 3 | Feb 7, 2020 | clinicaltrials |
| NCT02219724 | A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 174 | Genentech, Inc.INDUSTRY | 6 | Feb 5, 2020 | clinicaltrials |
| NCT01292655 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 94 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 27, 2020 | clinicaltrials |
| NCT02383212 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | completed | Phase 1 | 398 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 27, 2020 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT03119467 | Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 21 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Dec 27, 2019 | clinicaltrials |
| NCT02676869 | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma(TACTI-mel) | completed | Phase 1 | 24 | Immutep Australia Pty. Ltd.INDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT04175171 | Clinical Trial of Comparative Study of GB221 Pharmacokinetics | completed | Phase 1 | 32 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT01988896 | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 153 | Hoffmann-La RocheINDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT02313012 | Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors | terminated | Phase 1 | 19 | CelgeneINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT03505528 | An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer(Epi-PRIMED) | completed | Phase 1 | 8 | EpiAxis TherapeuticsINDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | completed | Phase 1 | 33 | GlaxoSmithKlineINDUSTRY | 8 | Oct 9, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT02492789 | A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients | completed | Phase 1 | 49 | Atridia Pty Ltd.INDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02759666 | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 30 | Atridia Pty Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02262910 | Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 35 | Aptevo TherapeuticsINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT03154086 | A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers | completed | Phase 1 | 68 | GlaxoSmithKlineINDUSTRY | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01236352 | Multiple Ascending Dose of BMS-911543 | terminated | Phase 1 / Phase 2 | 98 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 31, 2019 | clinicaltrials |
| NCT01271803 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 131 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2019 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT00832559 | A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)(VLA-X06) | terminated | Phase 1 | 4 | ViralyticsINDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03239223 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 16 | Antiva BiosciencesINDUSTRY | 2 | Jul 10, 2019 | clinicaltrials |
| NCT00438009 | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | completed | Phase 1 | 9 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT01966445 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | completed | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Jul 1, 2019 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials